Pacific Biosciences/$PACB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pacific Biosciences
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Ticker
$PACB
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
575
ISIN
US69404D1081
Website
PACB Metrics
BasicAdvanced
$366M
-
-$2.34
2.10
-
Price and volume
Market cap
$366M
Beta
2.1
52-week high
$2.41
52-week low
$0.85
Average daily volume
9.8M
Financial strength
Current ratio
6.68
Quick ratio
8.64
Long term debt to equity
762.905
Total debt to equity
762.905
Interest coverage (TTM)
-55.46%
Profitability
EBITDA (TTM)
-229.19
Gross margin (TTM)
27.63%
Net profit margin (TTM)
-431.71%
Operating margin (TTM)
-177.60%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-13.36%
Return on equity (TTM)
-177.61%
Valuation
Price to revenue (TTM)
2.253
Price to book
3.99
Price to tangible book (TTM)
-1.48
Price to free cash flow (TTM)
-1.874
Free cash flow yield (TTM)
-53.36%
Free cash flow per share (TTM)
-65.10%
Growth
Revenue change (TTM)
-23.99%
Earnings per share change (TTM)
104.89%
3-year revenue growth (CAGR)
4.19%
10-year revenue growth (CAGR)
8.63%
3-year earnings per share growth (CAGR)
41.03%
10-year earnings per share growth (CAGR)
9.61%
What the Analysts think about PACB
Analyst ratings (Buy, Hold, Sell) for Pacific Biosciences stock.
Bulls say / Bears say
Pacific Biosciences' consumable revenue increased by 10% year-over-year in Q3 2024, indicating strong demand for their products. (GuruFocus)
The company has made significant progress in reducing production costs and operating expenses, aiming to be cash flow positive by the end of 2026. (GuruFocus)
Strategic partnerships, such as with the National Institute of Health of Korea and Singapore's National Precision Medicine Program, are expanding PacBio's market reach and application of its technologies. (GuruFocus)
Scotiabank reduced its price target for Pacific Biosciences from $15.00 to $8.00, reflecting concerns over missed revenue expectations and delayed instrument sales. (Investing.com)
The company reported a 10.3% decrease in revenue for Q1 2025 compared to the previous year, indicating potential challenges in maintaining sales growth. (TradingView News)
Insider selling activity, such as the sale of 34,405 shares by an insider in January 2025, may signal a lack of confidence in the company's near-term prospects. (The AM Reporter)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
PACB Financial Performance
Revenues and expenses
PACB Earnings Performance
Company profitability
PACB News
AllArticlesVideos
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
GlobeNewsWire·1 month ago
First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand
GlobeNewsWire·2 months ago
PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pacific Biosciences stock?
Pacific Biosciences (PACB) has a market cap of $366M as of June 26, 2025.
What is the P/E ratio for Pacific Biosciences stock?
The price to earnings (P/E) ratio for Pacific Biosciences (PACB) stock is 0 as of June 26, 2025.
Does Pacific Biosciences stock pay dividends?
No, Pacific Biosciences (PACB) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Pacific Biosciences dividend payment date?
Pacific Biosciences (PACB) stock does not pay dividends to its shareholders.
What is the beta indicator for Pacific Biosciences?
Pacific Biosciences (PACB) has a beta rating of 2.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.